The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Cyberonics (NSDQ:CYBX) saw some significant interest from Wall Street today after posting record sales for its 2nd quarter and increasing its projections for the rest of the year.
Shares of Cyberonics (NSDQ:CYBX) are up some 6% today after the medical device company said an ex-sales rep voluntarily dismissed a wrongful termination lawsuit.
Andrew Hagerty sued the Houston, Texas-based company last August, alleging that Cyberonics canned him after he refused to sell unneeded replacement batteries for implanted pulse generators designed to treat epilepsy.
ConMed (NSDQ:CNMD) said it’s closed its 27¢-per-share tender offer for Viking Systems (OTC:VKNG), leaving it with about 84% of shares in the medical imaging maker.
The highly anticipated U.S. Supreme Court decision on the legality of President Barack Obama’s Affordable Care Act will ripple through different areas of U.S. Healthcare, with different outcomes tied to each possibility.
The Supremes will this month unveil their decision on theconstitutionality of the healthcare reform law’s individual insurance mandate, which would require nearly all U.S. citizens to carry health insurance. Should they strike down the measure, they will further decide whether the rest of the health law can survive on its own.
The new slate of directors for Olympus Corp. (TYO:7733) is already drawing fire from foreign investors in the endoscopy giant, after its entire board resigned en masse over a $1.7 billion accounting scandal that’s slashed its valuation by about 50% since October.
Boston Scientific Corp.’s (NYSE:BSX) Alair asthma management system won reimbursement from the Centers for Medicare & Medicaid Services, effective at the start of this year.
The Alair system delivers precise thermal energy lung to tissue via bronchoscope to reduce excessively smooth muscle, decreasing the airway’s ability to constrict.
Shares of orthopedic device makers are up this morning after bellwether Biomet Inc. reported preliminary sales numbers indicating 3.8% growth for its fiscal second quarter.
The FDA approved a new Medtronic (NYSE:MDT) stent for peripheral arterial disease and green-lighted a pivotal clinical trial of a so-called “artificial pancreas” for Type I diabetics.
The pair of regulatory wins follow a decision that didn’t go Medtronic’s way, after an FDA panel last week recommended against approval of one of its cardiac ablation devices for a type of atrial fibrillation.
